These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2784999)

  • 1. Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.
    Fukui H; Reynolds CW; Lenz B; Schneider M; Talmadge JE
    Cancer Immunol Immunother; 1989; 29(1):1-6. PubMed ID: 2784999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect in peritoneal carcinomatosis of intraperitoneal administration of a streptococcal preparation, OK-432: I. Experimental study in the rat.
    Saji S; Umemoto T; Kida H; Sakata K
    J Surg Oncol; 1985 Sep; 30(1):46-51. PubMed ID: 4079418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1019-24. PubMed ID: 3500354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.
    Saito M; Ichimura O; Kataoka M; Moriya Y; Ueno K; Sugawara Y; Nanjo M; Ishida N
    Cancer Immunol Immunother; 1986; 22(3):161-8. PubMed ID: 2425968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
    Ishida N; Saito M; Nanjo M
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). I. Sequential effector mechanisms following a single OK-432 injection in F344 rats leading to the rejection of syngeneic MADB106 tumor cells.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1011-7. PubMed ID: 3479632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
    Hayashi Y; Torisu M
    Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation by OK-432 of generation of culture-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between the presence of intracellular OK-432 and antitumor activity of peritoneal macrophages.
    Toge T; Hamamoto S; Aratani K; Yamada H; Fujita T; Hattori T
    Int J Immunopharmacol; 1986; 8(6):599-603. PubMed ID: 3793325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of NK activation by OK-432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells.
    Bonavida B; Katz J; Hoshino T
    Cell Immunol; 1986 Oct; 102(1):126-35. PubMed ID: 3492275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of OK-432 on cytotoxic activity in cancer patients without tumor burden.
    Fujieda S; Saito H; Isobe Y; Nakagawara G; Nishi O; Nagahara K; Watanabe Y; Hoshino T
    Anticancer Res; 1992; 12(6B):1941-5. PubMed ID: 1341892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients.
    Watanabe N; Niitsu Y; Yamauchi N; Neda H; Sone H; Urushizaki I; Yamamoto A; Nagamuta M; Sugawara Y
    Immunopharmacol Immunotoxicol; 1988; 10(1):53-65. PubMed ID: 3361071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
    Ujiie T
    Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.
    Wakasugi H; Oshimi K; Miyata M; Morioka Y
    J Clin Immunol; 1981 Jul; 1(3):154-62. PubMed ID: 6174541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OK-432 and IL-2-augmented cytotoxicity of human natural killer cells and cytotoxic T lymphocytes at the clonal level.
    Gravekamp C; Vreugdenhil R; Bolhuis RL
    FEMS Microbiol Immunol; 1988 Jan; 1(1):31-9. PubMed ID: 2978812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of tumor necrosis factor by administration of OK-432 in cancer patients.
    Kokunai I; Shimano T; Sekimoto K; Takeda T; Kobayashi T; Yayoi E; Yamamoto A; Mori T
    J Clin Lab Immunol; 1986 Dec; 21(4):169-71. PubMed ID: 3560194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
    Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N
    J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful adoptive immunotherapy with OK432-inducible activated natural killer cells in tumor-bearing mice.
    Yamaue H; Tanimura H; Iwahashi M; Tsunoda T; Tani M; Inoue M
    Biotherapy; 1990; 2(1):51-61. PubMed ID: 2400628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
    Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
    Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.